MediWound Ltd. (MDWD) is a publicly traded Healthcare sector company. As of May 21, 2026, MDWD trades at $16.89 with a market cap of $210.78M and a P/E ratio of 0.00. MDWD moved +1.20% today. Year to date, MDWD is -8.60%; over the trailing twelve months it is -19.07%. Its 52-week range spans $14.14 to $22.51. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces MDWD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MediWound Showcases Superior EscharEx Debridement Data Over SANTYL, Supports Phase III: MediWound will present new preclinical and clinical data demonstrating EscharEx’s superior debridement versus SANTYL, targeted molecular pathway activation, and improved scar outcomes at WHS, SAWC and EWMA conferences. The findings underpin its ongoing Phase III VALUE trial in venous leg ulcers and planned diabetic foot and pressure ulcer expansions.
| Metric | Value |
|---|---|
| Price | $16.89 |
| Market Cap | $210.78M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.51 |
| 52-Week Low | $14.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover MDWD: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.